Jaguar Health, Inc. (JAGX)
Stock Price Chart
Key Info
| Market Cap | 52.74M |
| Revenue (ttm) | 5.05M |
| Net Income (ttm) | -38.17M |
| Shares Out | 32.16M |
| EPS (ttm) | -5.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 5, 2020 |
| Last Price | $0.727 |
| Previous Close | $0.680 |
| Change ($) | 0.048 |
| Change (%) | 6.99% |
| Day's Open | 0.680 |
| Day's Range | 0.670 - 0.744 |
| Day's Volume | 5,395,226 |
| 52-Week Range | 0.351 - 1.790 |
More Stats
| Market Cap | 52.74M |
| Enterprise Value | 58.89M |
| Earnings Date (est) | Nov 12, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 32.16M |
| Float | 16.07M |
| EPS (basic) | -13.31 |
| EPS (diluted) | -5.20 |
| FCF / Share | -1.41 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 191,092 |
| Short Ratio | 0.25 |
| Short % of Float | 3.74% |
| Beta | 0.86 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 10.43 |
| PB Ratio | 4.46 |
| Revenue | 5.05M |
| Operating Income | -30.83M |
| Net Income | -38.17M |
| Free Cash Flow | -21.29M |
| Net Cash | -6.16M |
| Net Cash / Share | -0.08 |
| Gross Margin | -74.84% |
| Operating Margin | -609.92% |
| Profit Margin | -887.10% |
| FCF Margin | -421.31% |
| ROA | -41.14% |
| ROE | -235.60% |
| ROIC | -24,943.20% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|
| Revenue | 5.78 | 4.42 | 4.36 | 0.14 | 0.26 | - |
| Revenue Growth | 30.78% | 1.26% | 2981.61% | -45.23% | - | - |
| Gross Profit | 1.96 | 1.65 | 3.48 | 0.09 | 0.13 | - |
| Operating Income | -28.95 | -30.82 | -34.25 | -13.59 | -12.45 | -8.32 |
| Net Income | -38.54 | -32.15 | -21.97 | -14.73 | -16.29 | -8.61 |
| Shares Outstanding | 4.97 | 0.21 | 0.04 | 0.01 | 0.01 | - |
| Earnings Per Share | -9.01 | -153.27 | -531.14 | -1,417.00 | -2,834.01 | -3,400.81 |
| Operating Cash Flow | -20.46 | -22.73 | -9.82 | -14.41 | -14.32 | -5.36 |
| Capital Expenditures | - | -0.01 | - | -0.10 | - | -0.06 |
| Free Cash Flow | -20.46 | -22.74 | -9.82 | -14.52 | -14.32 | -5.41 |
| Cash & Equivalents | 3.88 | 2.57 | 0.76 | 1.46 | 10.70 | 0.85 |
| Total Debt | 7.57 | 16.08 | 16.41 | 3.89 | 5.95 | 0.82 |
| Net Cash / Debt | -3.68 | -13.52 | -15.65 | -2.42 | 4.74 | 0.03 |
| Assets | 36.41 | 41.04 | 43.63 | 3.56 | 12.41 | 4.42 |
| Liabilities | 15.84 | 26.66 | 26.37 | 6.02 | 8.01 | 5.35 |
| Book Value | 10.67 | 5.38 | 17.26 | -2.45 | 4.40 | -8.24 |
Company Profile
Company Details
| Full Name | Jaguar Health, Inc. |
| Country | United States |
| Employees | 29 |
| CEO | Lisa A. Conte |
Stock Information
| Ticker Symbol | JAGX |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NASDAQ: JAGX |
Description
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. It operates through two reportable segments, Human Health and Animal Health. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals. Its human health product pipelines include crofelemer, which is in Phase III clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, idiopathic/functional diarrhea, and irritable bowel; and SB-300, a second-generation anti-secretory agent for various indications, including cholera. The company's animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of chemotherapy-induced diarrhea in dogs; and Equilevia, a non-prescription product for total gut health in equine athletes. In addition, its products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.